Valeo Pharma Inc. (VPH.TO)
- Previous Close
0.0950 - Open
0.0950 - Bid 0.1050 x --
- Ask 0.1150 x --
- Day's Range
0.0950 - 0.1150 - 52 Week Range
0.0600 - 0.5200 - Volume
259,461 - Avg. Volume
60,856 - Market Cap (intraday)
11.346M - Beta (5Y Monthly) 2.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3200 - Earnings Date Jun 11, 2024 - Jun 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.50
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.
www.valeopharma.com100
Full Time Employees
October 31
Fiscal Year Ends
Sector
Recent News: VPH.TO
Performance Overview: VPH.TO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VPH.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VPH.TO
Valuation Measures
Market Cap
9.37M
Enterprise Value
65.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.15
Price/Book (mrq)
--
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
-5.74
Financial Highlights
Profitability and Income Statement
Profit Margin
-52.37%
Return on Assets (ttm)
-23.07%
Return on Equity (ttm)
--
Revenue (ttm)
54.29M
Net Income Avi to Common (ttm)
-28.43M
Diluted EPS (ttm)
-0.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
9.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.8M
Research Analysis: VPH.TO
Company Insights: VPH.TO
VPH.TO does not have Company Insights